

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

September 5, 2017

In the Matter of

Bohai Pharmaceuticals Group Inc.,

File No. 500-1

**ORDER OF SUSPENSION OF
TRADING**

It appears to the Securities and Exchange Commission (“Commission”) that there is a lack of current and accurate information concerning the securities of Bohai Pharmaceuticals Group Inc. (“BOPH¹”) (CIK No. 1443242), a defaulted Nevada corporation located in Yantai, Shandong Province, China with a class of securities registered with the Commission pursuant to Securities Exchange Act of 1934 (“Exchange Act”) Section 12(g) because it is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q for the period ended September 30, 2014. On May 25, 2017, the Commission’s Division of Corporation Finance sent a delinquency letter to BOPH requesting compliance with its periodic filing requirements, but BOPH did not receive the delinquency letter due to its failure to maintain a valid address on file with the Commission as required by Commission rules (Rule 301 of Regulation S-T, 17 C.F.R. Section 232.301 and Section 5.4 of EDGAR Filer Manual). As of August 30, 2017, the common stock of BOPH was quoted on OTC Link operated by OTC Markets Group Inc. (formerly “Pink Sheets”), had six market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

¹ The short form of the issuer’s name is also its stock symbol.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company. Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT on September 6, 2017, through 11:59 p.m. EDT on September 19, 2017.

By the Commission.

Brent J. Fields
Secretary